Date: 2013-06-27
Type of information: Collaboration agreement
Compound:
Company: Vedanta Biosciences (USA - MA) Johnson & Johnson Innovation center, a J&J company (USA - NJ)
Therapeutic area: Autoimmune diseases - Inflammatory diseases - Infectious diseases
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On June 27, 2013, Vedanta announced that Johnson & Johnson Development Corporation has made an investment in Vedanta as part of a collaboration with the Johnson & Johnson Innovation center in Boston to support the advancement of a novel class of therapies that modulate pathways of interaction between the human microbiome and the human immune system. Vedanta’s programs are based on fundamental discoveries in the field of mucosal immunology. The discoveries illuminate mechanisms the immune system uses to differentiate between “good” and “bad” microbes. When these mechanisms are impaired, autoimmune and inflammatory diseases result. Vedanta has developed a discovery platform to mine these unexplored mechanisms. The platform enables investigation of novel targets and discovery of immunomodulatory microbiome-derived compositions. Vedanta’s lead program, VE-202, is a novel therapy for the treatment of IBD and other autoimmune and inflammatory diseases. Vedanta owns a broad portfolio of foundational intellectual property that places the company in a strong position to develop a robust pipeline of therapies based on how the human immune system interacts with its microbial residents.
Financial terms:
Latest news:
